Make more informed purchasing decisions with our new product availability and delivery estimate feature, now available on all product pages, in your cart, and during checkout.
Sign In
New to ºÚÁϳԹÏ?
Register for an account to quickly and easily purchase products online and for one-click access to all educational content.
New look, same high quality and support! You may notice that your instrument or reagent packaging looks slightly different from images displayed on the website, or from previous orders. We are updating our look but rest assured, the products themselves and how you should use them have not changed. Learn more
Request Pricing
Thank you for your interest in this product.
Please provide us with your contact information and your local representative
will contact you with a customized quote. Where appropriate, they can also assist you with a(n):
Estimated delivery time for your area
Product sample or exclusive offer
In-lab demonstration
By submitting this form, you are providing your consent to ºÚÁÏ³Ô¹Ï Canada Inc. and its subsidiaries and affiliates (¡°ºÚÁϳԹϡ±) to collect and use your information, and send you newsletters and emails in accordance with our privacy policy. Please contact us with any questions that you may have. You can unsubscribe or change your email preferences at any time.
Easily isolate highly purified and magnetic particle-free human Th17 (CD4+CXCR3-CCR6+) cells from fresh human peripheral blood mononuclear cells (PBMCs) or leukapheresis samples by immunomagnetic positive selection, with the EasySep? Human Th17 Enrichment Kit II. Widely used in published research for more than 20 years, EasySep? combines the specificity of monoclonal antibodies with the simplicity of a column-free magnetic system.
In this EasySep? positive selection procedure, desired cells are first labeled with antibody complexes recognizing CCR6 and magnetic particles called EasySep? Releasable RapidSpheres?. Unlike traditional magnetic particles, which stay bound to the target cells, these RapidSpheres? have a releasable feature. After separation using an EasySep? magnet, bound magnetic particles are removed from the EasySep?-isolated CCR6+ cells using a release agent, and unwanted non-CD4+ T cells, CD45RA+ cells, and CXCR3+ cells are targeted for depletion. The final isolated fraction contains highly purified IL-17-producing Th17 cells, which are immediately ready for downstream applications.
This product can be used in place of the EasySep? Human Th17 Cell Enrichment Kit (Catalog #18162) for even faster cell isolations.
Learn more about how immunomagnetic EasySep? technology works. Alternatively, choose ready-to-use, ethically sourced, primary Human Peripheral Blood Th17 Cells, Frozen isolated with EasySep? Human Th17 Enrichment Kit II. Explore additional products optimized for your workflow, including those for culture media, supplements, antibodies, and more.
Figure 1. Typical EasySep™ Human Th17 Cell Enrichment Profile
Starting with fresh PBMCs, the Th17 cell content (CD4+CXCR3-CCR6+) of the isolated fraction typically ranges from 96 - 98%. Following overnight stimulation with PMA-Ionomycin, 6 - 19% of the isolated cells are IL-17+ by intracellular flow cytometry. These values vary widely among donors. IFN-¦Ã-producing cells are typically < 5% of the enriched fraction.
This product is designed for use in the following research area(s) as part
of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we
offer to support each research area.
Th17 cell-derived miR-155-5p modulates interleukin-17 and suppressor of cytokines signaling 1 expression during the progression of systemic sclerosis.
L. Han et al.
Journal of clinical laboratory analysis 2022 jun
Abstract
BACKGROUND miR-155-5p is associated with autoimmune diseases. T helper 17 (Th17) cells, interleukin (IL)-17, and suppressor of cytokines signaling 1 (SOCS1) have important roles in the pathogenesis of systemic sclerosis (SSc). The purpose of this study was to explore the role of miR-155-5p in the regulation of IL-17 and SOCS1 expression in Th17 cells and the subsequent effect on SSc disease progression. METHODS Th17 cells were isolated from peripheral blood mononuclear cells of SSc patients and healthy controls (HCs). RT-qPCR and western blotting were used to examine the expression patterns of miR-155-5p, IL-17, and SOCS1. Luciferase reporter assays were performed to confirm SOCS1 as a target of miR-155-5p. RNA pull-down assays were performed to detect the interaction of IL-17 and SOCS1 with miR-155-5p. In situ hybridization was performed to analyze the co-expression pattern of miR-155-5p and IL17A in Th17 cells. RESULTS The levels of Th17 cell-derived miR-155-5p were significantly up-regulated in SSc patients compared with HCs, and its levels were negatively correlated with SOCS1?levels. Meanwhile, miR-155-5p positively regulated IL-17 expression levels in Th17 cells isolated from SSc patients as the disease progressed. Using pmirGLO vectors, SOCS1 was confirmed as a target of miR-155-5p. The binding status of IL-17 and SOCS1 to miR-155-5p was related to SSc progression. An increase in the co-localization of miR-155-5p and IL-17 was associated with greater SSc progression. CONCLUSIONS IL-17 and SOCS1 expression modulated by Th17 cell-derived miR-155-5p are critical for SSc progression, which may provide novel insights into the pathogenesis of SSc.
Mouse monoclonal IgG2b antibody against human, rhesus, cynomolgus CD4
Item added to your cart
EasySep? Human Th17 Cell Enrichment Kit II
New look, same high quality and support! You may notice that your instrument or reagent packaging looks slightly different from images displayed on the website, or from previous orders. We are updating our look but rest assured, the products themselves and how you should use them have not changed. Learn more
Quality Statement:
PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT ºÚÁϳԹÏ, REFER TO WWW.ºÚÁϳԹÏ.COM/COMPLIANCE.